Significant hemolysis is present during irreversible electroporation of cardiomyocytes in vitro

Heart Rhythm. 2025 Feb;22(2):466-474. doi: 10.1016/j.hrthm.2024.08.019. Epub 2024 Aug 13.

Abstract

Background: Pulsed field ablation (PFA) of atrial fibrillation is a new method in clinical practice. Despite a favorable safety profile of PFA in atrial fibrillation ablation, rare cases of renal failure, probably due to hemolysis, have recently been reported.

Objective: The aim of this study was to determine the rate of hemolysis and cardiac cell death during in vitro PFA with different electric field intensities.

Methods: Blood samples from healthy volunteers and mouse HL-1 cardiomyocyte cell lines were subjected to in vitro irreversible electroporation using 216 bipolar pulses, each lasting 2 μs with intervals of 5 μs, repeated 20 times at a frequency of 1 Hz. These pulses varied from 500 V to 1500 V. Cell-free hemoglobin levels were assessed spectrophotometrically, and red blood cell microparticles were evaluated by flow cytometry. Cardiomyocyte death was quantified with propidium iodide.

Results: Pulsed field energy (1000 V/cm, 1250 V/cm, and 1500 V/cm) was associated with a significant increase in cell-free hemoglobin (0.32 ± 0.16 g/L, 2.2 ± 0.96 g/L, and 5.7 ± 0.39 g/L; P < .01) and similar increase in the concentration of red blood cell microparticles. Significant rates of cardiomyocyte death were observed at electric field strengths of 750 V/cm, 1000 V/cm, 1250 V/cm, and 1500 V/cm (26.5% ± 5.9%, 44.3% ± 6.2%, 55.5% ± 6.9%, and 74.5% ± 17.8% of cardiomyocytes; P < .01).

Conclusion: The most effective induction of cell death in vitro was observed at 1500 V/cm. This intensity was also associated with a significant degree of hemolysis.

Keywords: Atrial fibrillation; Cardiomyocytes; Hemolysis; Irreversible electroporation; Pulsed field ablation.

MeSH terms

  • Animals
  • Atrial Fibrillation* / surgery
  • Catheter Ablation* / adverse effects
  • Catheter Ablation* / methods
  • Electroporation* / methods
  • Hemolysis*
  • Humans
  • Male
  • Mice
  • Myocytes, Cardiac* / pathology